ERLI PLUS XR 12.5/1000

Erli Plus XR 12.5/1000 is a combination medication that contains two active ingredients: Empagliflozin & Metformin. It is an extended-release formulation, which means it provides a gradual release of the drugs into the body over an extended period. Empagliflozin belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, while Metformin is a biguanide antidiabetic medication. This combination is used to help manage type 2 diabetes mellitus in adults.

Uses:

Erli Plus XR 12.5/1000 is used in the treatment of type 2 diabetes mellitus to help control blood sugar levels. It is typically prescribed for adults when lifestyle changes such as diet and exercise alone are insufficient to control their diabetes. The two active ingredients work together to lower blood glucose levels through different mechanisms:

1. Empagliflozin: It works by inhibiting SGLT2 in the kidneys, reducing glucose reabsorption, and promoting the excretion of excess glucose through urine.
2. Metformin: It helps decrease the production of glucose in the liver and improves the body’s sensitivity to insulin, leading to better utilization of glucose by the cells.

Side Effects:

As with any medication, Erli Plus XR 12.5/1000 may cause side effects in some individuals. It is essential to seek medical attention if any of the following side effects are experienced and become bothersome:

1. Common Side Effects:
   • Increased urination
   • Urinary tract infections
   • Genital yeast infections in both men and women
   • Diarrhea or upset stomach
   • Headache
   • Nasopharyngitis (common cold symptoms)
2. Serious Side Effects (Rare – Seek Immediate Medical Attention):
   • Signs of ketoacidosis (e.g., fruity breath, confusion, rapid breathing)
   • Severe allergic reactions (rash, itching, swelling of the face/tongue/throat)
   • Lactic acidosis (unusual muscle pain, difficulty breathing, stomach discomfort)
   • Dehydration or excessive thirst

When Not To Use:

Erli Plus XR 12.5/1000 should not be used under the following circumstances:

1. Type 1 Diabetes: This medication is not suitable for the treatment of type 1 diabetes, as it is not effective in such cases.
2. Diabetic Ketoacidosis: If a person experiences diabetic ketoacidosis (a serious complication of diabetes characterized by high ketone levels in the blood), Erli Plus XR 12.5/1000 should not be used.
3. Severe Kidney Impairment: Individuals with severe kidney impairment or kidney failure should avoid using this medication due to the risk of adverse effects.
4. Severe Liver Disease: People with severe liver disease should not take Erli Plus XR 12.5/1000, as it may worsen the condition.
5. Allergy to Components: If a person is known to be allergic to Empagliflozin, Metformin, or any other ingredient in the formulation, they should avoid using this medication.

Always follow the prescribed dosage and inform the healthcare professional about any existing medical conditions and medications being taken to ensure safe and effective use of Erli Plus XR 12.5/1000. Regular monitoring of blood glucose levels and kidney function is essential while on this medication. If there are any concerns or questions about the use of this combination, seek medical advice promptly.